Lisa Conroy

Lisa Conroy is the Director of Communications at Antidote. She is a seasoned health communications strategist dedicated to understanding the reasons people make the health choices they do, and determining what that means in terms of how scientific data should be communicated. Prior to her role at Antidote, Lisa ran the TEDMED Great Challenges program, a public health initiative funded by RWJF. She also has experience working in pharmaceutical public relations in the areas of respiratory diseases, oncology, and HIV. Lisa holds an MPH from Columbia and a BA in English and International Studies from Northwestern.

How a 67% randomization rate led to 3 months saved in a Parkinson’s trial [patient recruitment case study]

Parkinson’s disease is a disorder of the central nervous system that affects movement, with symptoms such as tremor, slow movement, stiffness, and loss of balance. Current treatments come with side effects, and there is no cure. This means research is critical to developing new and better treatments for the nearly one million people in the US living with Parkinson’s disease. 

Continue reading

COVID-19 and mental health: A look at the pandemic’s impact on mental health, how we’re treating it, and how it’s affecting those in clinical trials [whitepaper]

What impact has COVID-19 had on our collective mental health? How has treatment been adapted to meet new needs? And what does this all mean for clinical trial participants?

Continue reading

Decentralizing research: How reducing patient burden improves trial diversity [whitepaper]

Could the alternative clinical trial approaches necessitated by the COVID-19 pandemic help tip the scales towards fair access to clinical trials? In our latest whitepaper, “Decentralizing research: How reducing patient burden improves trial diversity,” we take a close look at the current state of diversity in clinical trials, then explore how the decreased participant burden of decentralized ...

Continue reading

Patient recruitment: Today’s trends, tomorrow’s potential [interview with ACRPtv]

By some estimations, 80% of clinical trials are delayed or closed because researchers can’t find enough patients to take part in their clinical trials. This, of course, means that trial sponsors are losing money and sites are wasting time screening ineligible patients. But, it also means that countless patients continue to wait for new and potentially better treatment options.

Continue reading

How to find and join lupus support groups

Living with lupus can be difficult. It’s an “invisible illness” — meaning those around you can’t see your fatigue or your muscle and joint pain or any of the many other symptoms. This can be a lonely experience, and that’s why it’s so important for people with lupus to connect with others who have the condition as well. 

Continue reading

Why your clinical trial advertising might be missing the mark

Are you spending time and money on clinical trial advertising that’s not delivering? It can be frustrating to put resources into spreading the word about your study, only to find that the patients who make it to your sites are not right for your trial. According to a survey Antidote conducted of 4,000+ patients, 52% of patients found out about clinical trial opportunities through an ...

Continue reading

The evolving role of partnerships in clinical trial patient engagement

An interview with Lindsey Wahlstrom-Edwards, Head of Partnerships at Antidote

Continue reading

How we cut our expected referral timeline in half [patient recruitment case study]

Idiopathic pulmonary fibrosis (IPF) is a progressive disease that causes scarring of the lungs. Over time, the scarring worsens and it can become difficult to breathe. IPF has no cure and limited treatment options, making clinical research especially critical. In this case study, a pharma company approached Antidote to identify 600 IPF patients who would be eligible for their study in just six ...

Continue reading

Patient engagement during COVID-19 [whitepaper]

Does a health crisis change digital engagement behaviors? How should digital marketers respond?

Continue reading

A delicate balance: How clinical trial patient engagement benefits from technology with a human touch [Whitepaper]

Can we apply customer service models to healthcare? And what would that mean for clinical trial patient recruitment? 

Continue reading

Get our latest posts in your inbox.